arrow
L

Leppert, David

university of basel
H指数:0
被引数:0

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Temelimab versus placebo in patients with post-COVID condition

Temelimab与安慰剂在新冠后综合征患者中的比较

2026-07-010
OAAI
Emerging CSF and Serum Biomarkers in Multiple Sclerosis

多发性硬化中新兴的脑脊液和血清生物标志物

2026-05-010
PRE
Serum Neurofilament Light Chain in Multiple Sclerosis: Superiority of Age- and BMI-Corrected Z Scores/Percentiles Over Absolute Cutoff Values for Prediction of Treatment Response

血清神经丝轻链在多发性硬化中的研究:年龄和BMI校正的Z分数/百分位数对预测治疗反应优于绝对截断值

2025-08-030
OAAI
Comparative effectiveness of teriflunomide and ocrelizumab on smoldering activity in multiple sclerosis: an observational study in the Swiss Multiple Sclerosis Cohort

特立氟胺和奥瑞利珠单抗对多发性硬化潜隐性活动比较效果:一项在瑞士多发性硬化队列中的观察性研究

2025-07-020
OAAI
Aberrant Complement Activation Is Associated With Structural Brain Damage in Multiple Sclerosis
2025-03-010
PRE
Serum Glial Fibrillary Acidic Protein and Neurofilament Light Chain Levels Reflect Different Mechanisms of Disease Progression under B-Cell Depleting Treatment in Multiple Sclerosis

血清胶质纤维酸性蛋白和神经丝轻链水平反映了多发性硬化b细胞耗竭治疗下疾病进展的不同机制

2024-10-164
OA
Contrast-Enhancing Lesion Segmentation in Multiple Sclerosis: A Deep Learning Approach Validated in a Multicentric Cohort

多发性硬化症中增强对比度的病变分割: 在多中心队列中验证的深度学习方法

2024-08-220
OAAI
Neurofilaments as biomarkers in neurological disorders - towards clinical application

神经丝作为神经系统疾病的生物标志物-面向临床应用

2024-04-1245
PRE
Complement Activation Is Associated With Disease Severity in Multiple Sclerosis
2024-03-018
OA
Association of Spinal Cord Atrophy and Brain Paramagnetic Rim Lesions With Progression Independent of Relapse Activity in People With MS
2024-01-0923
OAAI
Development and multi-center validation of a fully automated digital immunoassay for neurofilament light chain: toward a clinical blood test for neuronal injury

神经丝蛋白轻链全自动数字免疫分析的开发与多中心验证: 神经元损伤的临床血液检测

2023-09-1313
OA
Interleukin-3 coordinates glial-peripheral immune crosstalk to incite multiple sclerosis

Interleukin-3协调神经胶质-外周免疫串扰以激发多发性硬化症

IMMUNITY
IF26.3
2023-07-0120
PRE